Appili Therapeutics Inc Class A (TSE:APLI)
TSX:APLI
Want to see TSE:APLI full AI Analyst Report?
Top Page
Appili Therapeutics Inc Class A
(TSX:APLI)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.01
▼(-30.00% Downside)
Action:Reiterated
Date:06/28/26
The score is primarily held down by weak financial performance—persistent losses, mostly negative cash flow, and a strained balance sheet with negative equity and rising debt. Technicals also lean bearish with the stock trading below key moving averages and negative MACD. Valuation contributes additional risk because a negative P/E reflects ongoing unprofitability and there is no dividend support.
Positive Factors
Focused infectious-disease pipeline
A narrow, clinical-stage focus on unmet infectious-disease indications creates durable strategic clarity. Specialization can improve R&D efficiency, make the company an attractive partner/licensing target, and align it with persistent public-health and funding priorities for antibacterials, antivirals, and antifungals.
Negative Factors
Strained balance sheet
Negative equity and rising debt materially weaken financial flexibility. Over time this increases financing costs, raises default or covenant risk, and makes the company reliant on dilutive financing or expensive borrowing, constraining its ability to fund development without external support.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused infectious-disease pipeline
A narrow, clinical-stage focus on unmet infectious-disease indications creates durable strategic clarity. Specialization can improve R&D efficiency, make the company an attractive partner/licensing target, and align it with persistent public-health and funding priorities for antibacterials, antivirals, and antifungals.
Read all positive factors
Appili Therapeutics Inc Class A (APLI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.93M
Dividend YieldN/A
Average Volume (3M)72.91K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth140.47%
EPS Growth-56.48%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Appili Therapeutics Inc Class A Business Overview & Revenue Model
Company Description
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pi...
How the Company Makes Money
null...
Appili Therapeutics Inc Class A Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
12
Very Negative
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 244.18K | 100.44K | 827.41K | 334.18K | 1.39M |
| Gross Profit | 236.09K | 100.44K | 827.41K | 327.91K | 1.39M |
| EBITDA | -6.53M | 360.57K | -2.07M | -8.10M | -23.51M |
| Net Income | -4.24M | -2.62M | -3.78M | -9.24M | -25.12M |
Balance Sheet | |||||
| Total Assets | 1.97M | 3.03M | 1.49M | 3.13M | 8.28M |
| Cash, Cash Equivalents and Short-Term Investments | 40.00K | 1.23M | 94.49K | 2.47M | 6.66M |
| Total Debt | 12.94M | 12.29M | 8.18M | 7.67M | 4.98M |
| Total Liabilities | 19.30M | 16.43M | 12.42M | 10.53M | 11.55M |
| Stockholders Equity | -17.33M | -13.40M | -10.92M | -7.40M | -3.27M |
Cash Flow | |||||
| Free Cash Flow | -1.38M | 866.46K | -2.49M | -10.10M | -19.08M |
| Operating Cash Flow | -1.38M | 868.82K | -2.46M | -10.10M | -19.08M |
| Investing Cash Flow | 0.00 | -2.36K | -29.06K | -3.17K | 5.06M |
| Financing Cash Flow | 197.82K | 193.68K | 122.05K | 5.91M | 9.56M |
Appili Therapeutics Inc Class A Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
45.75
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.75 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APLI.
Appili Therapeutics Inc Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$5.07M | -0.19 | -111.11% | ― | ― | -79.26% | |
44 Neutral | C$717.12K | 1.37 | -10.30% | ― | ― | ― | |
42 Neutral | C$49.12M | -13.73 | ― | ― | -31.89% | 21.88% | |
41 Neutral | C$1.93M | -0.63 | 19.73% | ― | 140.47% | -56.48% | |
41 Neutral | C$6.15M | -2.38 | ― | ― | ― | ― | |
| ― | C$2.04M | -0.59 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:APLI
Appili Therapeutics Inc Class A
0.02
0.00
0.00%
TSE:XRTX
XORTX Therapeutics Inc
2.93
-3.17
-51.97%
TSE:KNE
Kane Biotech
0.03
-0.02
-40.00%
TSE:MIR
Medmira
0.07
>-0.01
-10.26%
TSE:VXL
Vaxil Bio
0.18
-0.02
-10.00%
TSE:BIOV
BioVaxys Technology
0.07
-0.28
-80.00%
Appili Therapeutics Inc Class A Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Appili Therapeutics Targets New Funding and Partnerships at World Vaccine Congress Washington
Positive
Mar 30, 2026
Appili Therapeutics will exhibit at the World Vaccine Congress Washington 2026, where its CEO and chief development officer plan to highlight recent collaborations and funding milestones while seeking additional non-dilutive financing. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.